5-Carboxamidotryptamine (5-CT) is a 5-HT1A, 5-HT1B, 5-HT1D, 5-HT5A, 5-HT7 receptor agonist. 5-Carboxamidotryptamine has a Ki of 4.6 nM for the cloned human 5-HT5A receptor. 5-Carboxamidotryptamine causes a dose-dependent decrease in rectal temperature in mice.

Physicochemical Properties

Molecular Formula	C11H13N3O
Molecular Weight	203.24
Exact Mass	203.106
CAS #	74885-09-9
Related CAS #	5-Carboxamidotryptamine maleate;74885-72-6
PubChem CID	1809
Appearance	Typically exists as solid at room temperature
Boiling Point	513.6ºC at 760 mmHg
Flash Point	264.4ºC
LogP	2.168
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	3
Heavy Atom Count	15
Complexity	244
Defined Atom Stereocenter Count	0
SMILES	C1=CC2=C(C=C1C(=O)N)C(=CN2)CCN
InChi Key	WKZLNEWVIAGNAW-UHFFFAOYSA-N
InChi Code	InChI=1S/C11H13N3O/c12-4-3-8-6-14-10-2-1-7(11(13)15)5-9(8)10/h1-2,5-6,14H,3-4,12H2,(H2,13,15)
Chemical Name	3-(2-aminoethyl)-1H-indole-5-carboxamide
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	5-HT1A Receptor 5-HT1B Receptor 5-HT1D Receptor 5-HT5A Receptor 5-HT7 Receptor
ln Vivo	5-Carboxamidotryptamine lowers mice's rectal temperature in a dose-dependent manner (0.03–3 mg/kg ip and 0.125–5 µg icv)[3]. In wild type mice, 5-carboxamidotryptamine (0.1–1 mg/kg; ip) lowers rectal temperature, but not in mice with 5-HT7 receptor knockouts[3]. 5. Cats' heart rates rise in response to carbamidotryptamine (0.0 1–1 μg/kg; iv), which consistently lowers their diastolic blood pressure and carotid artery vascular resistance. On the other hand, 5-HT (1-100 μg/kg; iv) induces tachycardia but has complicated and variable effects on carotid artery vascular resistance and diastolic blood pressure[5]. 5-Bronchoconstriction in cats is not brought on by carbamidotryptamine. 5-HT, on the other hand, results in dose-related bronchoconstriction[5].
Animal Protocol	Animal/Disease Models: Male Swiss Webster mice (20-25 g)[3] Doses: 0.03-3 mg/kg (ip) and 0.125-5 µg (icv) Route of Administration: ip and icv Experimental Results: Caused dose-dependent reduction in rectal temperature. Animal/Disease Models: 5-HT7 receptor knockout mice (background=50% 129SvEv/50% C57Bl/6J)[3] Doses: 0.1-1 mg/kg Route of Administration: ip and icv Experimental Results: decreased rectal temperature in wild type but not 5-HT7 receptor knockout mice.
References	[1]. Saxena PR,et al. Characterization of 5-hydroxytryptamine receptors in the cranial vasculature. Cephalalgia. 1989;9 Suppl 9:15-22. [2]. Saxena PR, et al. From serotonin receptor classification to the antimigraine drug sumatriptan. Cephalalgia. 1992 Aug;12(4):187-96. [3]. Guscott MR, Egan E, Cook GP, Stanton JA, Beer MS, Rosahl TW, Hartmann S, Kulagowski J, et al. The hypothermic effect of 5-CT in mice is mediated through the 5-HT7 receptor. Neuropharmacology. 2003 Jun;44(8):1031-7. [4]. Hurley PT, et al. Functional coupling of a recombinant human 5-HT5A receptor to G-proteins in HEK-293 cells. Br J Pharmacol. 1998 Jul;124(6):1238-44. [5]. Connor HE, et al. 5-Carboxamidotryptamine is a selective agonist at 5-hydroxytryptamine receptors mediating vasodilatation and tachycardia in anaesthetized cats. Br J Pharmacol. 1986 Feb;87(2):417-26.
Additional Infomation	5-carboxamidotryptamine is a member of tryptamines.

Solubility Data

Solubility (In Vitro)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Solubility (In Vivo)

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	4.9203 mL	24.6015 mL	49.2029 mL
	5 mM	0.9841 mL	4.9203 mL	9.8406 mL
	10 mM	0.4920 mL	2.4601 mL	4.9203 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.